August 18th 2020
By The Center for Biosimilars
Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.
August 15th 2020
By Skylar Jeremias
There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.
August 14th 2020
Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD.
August 13th 2020
By Tony Hagen
Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their own hands.
August 12th 2020
Pharmacy experts discuss their level of confidence with biosimilars and some of the hurdles that stand in the way of optimizing these lower-cost medicines.
August 11th 2020
Japanese investigators say more needs to be known about what happens post treatment with biosimilar infliximab in patients with rheumatoid arthritis (RA).
August 10th 2020
A rituximab biosimilar in diffuse large B-cell lymphoma (DLBCL) passes the real-world test with flying colors, according to Manfred Weslau, MD.
Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.
August 7th 2020
A new study showed that biosimilar interferon beta-1a (IFN-β-1a) may be effective in helping to treat patients with coronavirus disease 2019 (COVID-19).
August 6th 2020
Originator biologics should be monitored as closely as biosimilars, according to Gary Lyman, MD, MPH, of the Hutchinson Institute for Cancer Outcomes Research.
